Global Biomarker Collaboration and Licensing Partnering Analysis Report 2023 with Directory of 463 Deals Signed Since 2016

2023-11-15
PRNewswire
DUBLIN, Nov. 14, 2023 /PRNewswire/ -- The "Biomarker Collaboration and Licensing Deals 2016-2023" report has been added to
ResearchAndMarkets.com's offering.
This report contains a comprehensive listing of 463 biomarker deals announced since 2016 including financial terms where available including links to online deal records of actual biomarker partnering deals as disclosed by the deal parties.
Biomarker Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the biomarker deals entered into by the worlds leading biopharma companies. Fully revised and updated, the report provides details of biomarker deals from 2016 to 2023.
The report provides a detailed understanding and analysis of how and why companies enter biomarker deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. The report includes collaboration, development, research and licensing deals.
In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. The report also includes numerous table and figures that illustrate the trends and activities in biomarker deal making since 2016.
In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Chapter Highlights
Chapter 1 provides an introduction to the report.
Chapter 2 provides an overview of the trends in biomarker dealmaking since 2016.
Chapter 3 provides an overview of the leading biomarker deals since 2016. Deals are listed by headline value.
Chapter 4 provides a comprehensive listing of the top 25 most active companies in biomarker dealmaking with a brief summary followed by a comprehensive listing of biomarker deals, as well as contract documents available in the public domain.
Chapter 5 provides a comprehensive and detailed review of biomarker deals signed and announced since Jan 2016, where a contract document is available in the public domain.
Chapter 6 provides a comprehensive and detailed review of biomarker partnering deals signed and announced since Jan 2016. The chapter is organized by specific biomarker technology type in focus.
Biomarker Collaboration and Licensing Deals provides the reader with the following key benefits:
Understand deal trends since 2016
Browse biomarker collaboration and licensing deals
Benchmark analysis - identify market value of transactions
Financials terms - upfront, milestone, royalties
Directory of deals by company A-Z, deal type and therapy area
Leading deals by value
Most active dealmakers
Identify assets and deal terms for each transaction
Access contract documents - insights into deal structures
Due diligence - assess suitability of your proposed deal terms for partner companies
Save hundreds of hours of research time
Analyzing contract agreements allows due diligence of:
What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?
Key Topics Covered:
Executive Summary
Chapter 1 - Introduction
Chapter 2 - Trends in biomarker dealmaking
2.1. Introduction
2.2. Biomarker deals over the years
2.3. Most active biomarker dealmakers
2.4. Biomarker deals by deal type
2.5. Biomarker deals by therapy area
2.6. Biomarker deals by industry sector
2.7. Deal terms for biomarker deals
2.7.1 Biomarker deals headline values
2.7.2 Biomarker deal upfront payments
2.7.3 Biomarker deal milestone payments
2.7.4 Biomarker royalty rates
Chapter 3 - Leading biomarker deals
3.1. Introduction
3.2. Top biomarker deals by value
Chapter 4 - Most active biomarker dealmakers
4.1. Introduction
4.2. Most active biomarker dealmakers
4.3. Most active biomarker deals company profiles
Chapter 5 - Biomarker contracts dealmaking directory
5.1. Introduction
5.2. Biomarker contracts dealmaking directory
Chapter 6 - Biomarker dealmaking by technology type
Deal directory
Deal directory - Biomarker deals by company A-Z
Deal directory - Biomarker deals by deal type
Deal directory - Biomarker deals by therapy area
Companies Mentioned
Australian Centre for Plant Functional Genomics
Australian Imaging
Food Allergy Research & Education
VirtualScopics
John and Lucille Van Geest Foundation
Bill and Melinda Gates Foundation
PierianDx
Guardant Health
Dominantly Inherited Alzheimers Network
Renovar
San Martino Hospital
Veravas
Tel Hashomer
GeneData
CogState
Prostate Cancer Foundation (PCF)
Innovate UK
Biocrates
For more information about this report visit https://www.researchandmarkets.com/r/kw2oqm
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
机构
适应症
靶点
-
药物
-
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。